NCT04960644View on ClinicalTrials.gov

MTX and Steroid as First-line Therapy for aGVHD

PHASE3CompletedINTERVENTIONAL
Enrollment

157

Participants

Timeline

Start Date

June 25, 2021

Primary Completion Date

July 31, 2022

Study Completion Date

December 31, 2022

Conditions
Acute GVH Disease
Interventions
DRUG

MTX

MTX (5-10 mg/day,Dmax 10mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was CR

DRUG

Corticosteroid

corticosteroid Methylprednisolone 1 mg/kg/day was given for 10 days and then the dosage was gradually reduced according to patient's response

Trial Locations (1)

100044

Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Peking University People's Hospital

OTHER